S
Stefan Störk
Researcher at University of Würzburg
Publications - 373
Citations - 14615
Stefan Störk is an academic researcher from University of Würzburg. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 56, co-authored 312 publications receiving 11901 citations. Previous affiliations of Stefan Störk include University of Pennsylvania & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom,Stuart J. Connolly,Jackie Bosch,Gilles R. Dagenais,Robert G. Hart,Olga Shestakovska,Rafael Diaz,Marco Alings,Eva Lonn,Sonia S. Anand,Petr Widimsky,Masatsugu Hori,Alvaro Avezum,Leopoldo S. Piegas,Kelley R. Branch,Jeffrey L. Probstfield,Deepak L. Bhatt,Jun Zhu,Yan Liang,Aldo P. Maggioni,Patricio Lopez-Jaramillo,Martin O'Donnell,Ajay K. Kakkar,Keith A.A. Fox,Alexander Parkhomenko,Georg Ertl,Stefan Störk,Matyas Keltai,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Peter Verhamme,Dragos Vinereanu,Jae-Hyung Kim,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,P. Gabriel Steg,Kaj Metsärinne,Nancy Cook Bruns,Frank Misselwitz,Edmond Chen,Darryl P. Leong,Salim Yusuf +48 more
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Journal ArticleDOI
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries:
Kornelia Kotseva,Kornelia Kotseva,David R. Wood,David R. Wood,Dirk De Bacquer,Dirk De Bacquer,Guy De Backer,Guy De Backer,Lars Rydén,Lars Rydén,Catriona Jennings,Catriona Jennings,Viveca Gyberg,Philippe Amouyel,Jan Bruthans,Jan Bruthans,Almudena Castro Conde,Renata Cifkova,Renata Cifkova,J.W. Deckers,Johan De Sutter,Johan De Sutter,Mirza Dilic,Mirza Dilic,Maryna Dolzhenko,Andrejs Erglis,Andrejs Erglis,Zlatko Fras,Zlatko Fras,Dan Gaita,Nina Gotcheva,John A. Goudevenos,John A. Goudevenos,Peter U. Heuschmann,Aleksandras Laucevičius,Aleksandras Laucevičius,Seppo Lehto,Dragan Lovic,Davor Milicic,Davor Milicic,David Moore,Evagoras Nicolaides,Evagoras Nicolaides,Raphael Oganov,Andrzej Pajak,Nana Pogosova,Zeljko Reiner,Zeljko Reiner,Martin Stagmo,Stefan Störk,Lale Tokgozoglu,Lale Tokgozoglu,Dusko Vulic,Dusko Vulic +53 more
TL;DR: A large majority of coronary patients do not achieve the guideline standards for secondary prevention with high prevalences of persistent smoking, unhealthy diets, physical inactivity and consequently most patients are overweight or obese with a high prevalence of diabetes.
Journal ArticleDOI
Impact of Myocardial Fibrosis in Patients With Symptomatic Severe Aortic Stenosis
Frank Weidemann,Sebastian Herrmann,Stefan Störk,Markus Niemann,Stefan Frantz,Volkmar Lange,Meinrad Beer,Stefan Gattenlöhner,Wolfram Voelker,Georg Ertl,Jörg Strotmann +10 more
TL;DR: Myocardial fibrosis is an important morphological substrate of postoperative clinical outcome in patients with severe aortic stenosis and was not reversible after AVR over the 9 months of follow-up examined in this study.
Journal ArticleDOI
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment
Frank Weidemann,Markus Niemann,Frank Breunig,Sebastian Herrmann,Meinrad Beer,Stefan Störk,Wolfram Voelker,Georg Ertl,Christoph Wanner,Jörg Strotmann +9 more
TL;DR: Treatment of Fabry cardiomyopathy with recombinant α-galactosidase A should best be started before myocardial fibrosis has developed to achieve long-term improvement in myocardIAL morphology and function and exercise capacity.
Journal ArticleDOI
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial
Friedrich Koehler,Kerstin Koehler,Oliver Deckwart,Sandra Prescher,Karl Wegscheider,Bridget-Anne Kirwan,Sebastian Winkler,Eik Vettorazzi,Leonhard Bruch,Michael Oeff,Christian Zugck,Gesine Doerr,Herbert Naegele,Stefan Störk,Christian Butter,Udo Sechtem,Christiane E. Angermann,Guntram Gola,Roland Prondzinsky,Frank Edelmann,Sebastian Spethmann,Sebastian M Schellong,P. Christian Schulze,Johann Bauersachs,Brunhilde Wellge,Christoph Schoebel,Milos Tajsic,Henryk Dreger,Stefan D. Anker,Karl Stangl +29 more
TL;DR: The TIM-HF2 trial suggests that a structured remote patient management intervention, when used in a well defined heart failure population, could reduce the percentage of days lost due to unplanned cardiovascular hospital admissions and all-cause mortality.